described that the stable iodide was useful for surgery to treat the patient with exophthalmic goiter. Then many investigators have reported a clinical and chemical improvement in hyperthyroid patients during iodide therapy (Starr et al., 1924; Thompson et al., 1930) . However, it has soon been recognized that iodide is not an ideal drug for the treatment of such patients because of its incomplete and unsustained antithyroid effect (Thompson et al., 1930; Morton et al., 1944; Ingbar, 1972) . In addition, since thionamide agents (Astwood et al., 1943; MacKenzie and MacKenzie, 1943) or radioisotope therapy was introduced as more effective drugs for the treatment of hyperthyroidism than iodide alone, most of the physicians did not use iodide alone as a therapeutic drug for such patients. At present, the administration of iodide may be helpful in preparing patients for surgery and in the treatment of thyroid crisis etc.
The usual major clinical effect of iodide is an acute decrease in hormone secretion from the thyroid gland (Wartofsky et al., 1970) . On the other hand, the thionamide agents inhibit the formation of hormone in the gland, but they have no direct effect on iodine intake and on the release of hormone from the gland (VanderLaan and VanderLaan, 1947; Taurog et al., 1947; Richard and Ingbar, 1959; Iino et al,. 1961) .
In recent decade, thyroid hormone in serum has been able to be measured simply and accurately by competitive radioassay (Ekins, 1960; Brown et al., 1970) . MoreRover , there are increasing evidences that T3 plays an important role in thyroid physiology (Sterling, 1970) , that a minimum of about one-half of circulating T3 comes from peripheral T4 deiodination (Braverman et al., 1970; Pittman et al., 1971) , and that PTU inhibits deiodination of T4 (Furth et al., 1966; Oppenheimer et al., 1972) . These evidences indicated that the acute inhibition of both thyroidal hormone sectetion, formation and peripheral T3 production from T4 would cause a rapid fall in circulating T3 and T4 and also cause a rapid improvement in the thyrotoxic signs of patients. However, if the inhibition of thyroid hormone formation was incomplete with PTU, the additional amounts of iodide could lead to the synthesis of greater amounts of hormone than would be formed in the presence of PTU alone.
So, we compared the acute effects of iodide alone, PTU alone and PTU combined with iodide on thyroid function parameters such as T4, T3, T3-RU and FT4I in hyperthyroid patients with diffuse goiter decreased by both PTU and PTU+I-therapies until the end of four weeks. While the initial T4 levels in serum were not different in PTU and PTU+I-groups, the T4 level in the latter group was significantly lower one week after the therapy than in the former (p<0.01).
These striking differences found in three groups were clearly demonstrated in Fig. 1 and Table 2 .
Changes in serum T3 concentration in four-week treatments with iodide, PTU and PTU+I-The initial T3 levels were>760ng/100 ml in I-group,>592ng/100ml in PTU group and>615ng/100ml in PTU+I-group. As shown in Table 1 , the initial values in some patients exceeded the maximum range of the assay (800ng/100ml). Unfortunately, from the paucity of the specimens, remeasurements were not performed. Thus, statistical analysis of the initial T3 values in these groups was impossible. Although T3 levels in all three groups decreased consistently with each treatment for three or four weeks, the serum T3 level in PTU+I-group reached to the nearly normal range at the end of one week of treatment. While serum T3 levels in I group exceeded the normal range even after three-week treatment, it was noticed that T3 did not show the so-called"escape-phenomenon"in most of the patients in I-groups as shown in Fig. 2 and Table 2 .
Changes in serum T3-R U levels obsei ved during the course of treatments with iodide, PTU and PT U4-1-Almost the same declining pattern of T3-RU level in serum as T4 was observed in each group treated with iodide, PTU and PTU+I- (Table  2 and Fig.3 ). The striking decrease of T3-RU level was observed one week after the onset of iodide therapy and thereafter the value reincreased gradually despite of continued therapy. On the other hand, in two groups of PTU and PTU+I-treatments, the values consistently decreased until the end of four-week treatment. More pronounced decrease of T3-RU level was observed in PTU+I-group than in PTU alone group. 
Free thyroxine index (FT4I)
The declining patterns of FT4I were compared in these three groups as shown in Table 2 and Fig 4. Change inF T4I in each group was almost the same as that in T4 and T3-RU, respectively.
The socalled "escape-phenomenon"from the blocking action of iodide to form thyroid hormone was clearly demonstrated in the calculation of FT4I in I-group.
While the initial levels of FT4I in PTU and PTU+I-groups were not different, the value in the latter group was significantly lower one week after the therapy than the former (p<0.01). Effect of iodide withdrawal on the thyroid function in PTU-4+I group Our intesest was to know whether the thyroid function reincreased when iodide was withdrawn in PTU I-group.
At the end of the combined therapy, iodide administration was discontinued and only PTU was given to the patients for two to four weeks (150mg to 300mg/PTU/day). Then thyroid function parameters were measured and compared with those before iodide withdrawal.
As shown in Fig. 5 , no increase of thyroid function parameters was observed.
FREE THYROXINE INDEX 
Discussion
It has been well established that inorganic iodine inhibits temporally the thyroid hormone formation and release of the hormone from the thyroid gland. However, recently Nagataki et al. (1974) reported that thirty percent of untreated hyperthyroid patients did not escape from iodide inhibition of thyroid hormone secretion for more than eighteen months after the onset of iodide therapy (10mg potassium iodide/day). Emerson et al. (1975) In the present study, seven untreated patients with hyperthyroidism were given 1mg iodine as iodinated lecithine once daily.
One tablet of iodinated lethicine containing 1mg iodine in combination with unsaturated carbon atoms of lecithine had less side effects such as gastro-intestinal disturbances and eruption with inorganic iodides. At present, we considered that iodide slowly liberated from lecithine exhibited the antithyroid effects in the patient with hyperthyroidism.
Althouth, according to the reports by Nagataki et al. (1970 Nagataki et al. ( , 1974 , the reccurence of hyperthyroidism under iodide therapy might occur during its therapy and the percentage of reccurrence finally reached to about 70% in their series, the thyroid function in most of the patients treated with iodinated lecithine containing 1mg iodine reincreased within two weeks in the present study. Since Nagataki et al. (1974) used 10mg potassium iodide to treat hyperthyroidism, it should be considered that much larger amounts of iodine than the dose of 1mg might be required to reduce continually the serum levels of thyroid function parameters. As far as the present study is concerned, 1mg iodine might be enough to decrease the thyroid function parameters in the acute phase of therapy (Table 2 ; Figs. 1, 2, 3 and 4), but its action did not last more than one week in most of the patients It has been well established that the thionamide agents most easily inhibit the coupling of iodothyronine, next forming diiodotyrosine and last forming monoiodotyrosine (Richard and Ingbar, 1959; Iino et al., 1961) . We employed PTU (300mg in three divided doses/day) for the treatment of 17 untreated hyperthyroid patients. The data presented in Table 2 and in Figs. 1, 2, 3 and 4 indicated that PTU was a more effective and reliable antithyroid drug than iodide for a long term treatment.
Since 1mg iodine as iodinated lecithine reduced the thyroid function parameters such as T4, T3, T3-RU and FT4I to almost the same levels. as those found in PTU group within one week, we thus expected that the addition of 1mg iodine to PTU would lead to more pronounced reduction of the serum thyroidhormone levels than PTU or iodide alone. We were also anxious for the possibility that iodide, administered in combination with PTU, might reduce the efficacy of PTU even in a short term treatment, as suggested by Alexander et al., (1964) ; Alexander et al., (1965) and Harden et al., (1966) . The data from the present study suggested strongly that PTU+I-therapy was much more effective than PTU alone therapy to reduce the several thyroid functions. While the initial T4, T3-RU and FT4I levels in PTU and PTU+I-groups were not different, the T4 and FT4I levels in the latter group were significantly lower (p<0.01)at the end of one week therapy than those in the former. As shown in Tables  1, 5 out of 7 patients in I-group, 4 out of 14 in PTU group and 1 out of 13 patients in PTU+I-group showed T3 values exceeding 800ng/100ml.
In view of this difference of T3 among the groups, it might be possible that the hyperthyroidism in the last group was less severe than the other groups, resulting early recovery from the thyrotoxic state. However, considering the FT4I, the results were at least compatible with the thought that PTU plus iodide had a pronounced antithyroid effect at the early stage of the treatment.
No increase of all of thyroid function parameters was observed after iodide withdrawal in PTU+I-group, as shown in Fig. 5 . Also it was noticed that PTUwould prevent the so-called"escape-phenomenon"from iodide inhibition to occur when PTU was simultenously administered to patients with iodide. These results suggested that the small dose of iodide did 
